To confirm our hypothesis, Nrf2 activator of DMF, a drug approved for treatment of multiple sclerosis and psoriasis by activating Nrf2-responsive genes [83], was then subjected to mice with PM2.5 exposure. This evidence concerns the gene NFE2L2 and multiple sclerosis.